Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
CHARLOTTE, N.C., July 28, 2005 (PRIMEZONE) -- Chelsea Therapeutics International, Ltd. (OTCBB:IVRC) announced its shares will now be traded under the symbol (OTCBB:CHTP) effective at the opening of...
-
CHARLOTTE, N.C., July 27, 2005 (PRIMEZONE) -- Ivory Capital Corp. (OTCBB:IVRC) announced that its stockholders approved all proposals at its annual shareholders' meeting today, including...
-
CHARLOTTE, N.C., June 9, 2005 (PRIMEZONE) -- Chelsea Therapeutics, Inc. (OTCBB:IVRC) has begun dosing volunteers in its first Phase I clinical trial of CH-1504, an orally available inert antifolate...
-
CHARLOTTE, N.C., June 7, 2005 (PRIMEZONE) -- The United Kingdom's Medicines and Healthcare products Regulatory Agency, or MHRA, has approved a Clinical Trial Authorization, or CTA, application from...
-
CHARLOTTE, N.C., April 29, 2005 (PRIMEZONE) -- Chelsea Therapeutics, Inc. ("Chelsea") OTCBB:IVRC) has accepted an invitation to speak at the Rodman & Renshaw Techvest Global Healthcare Conference...
-
CHARLOTTE, N.C., Feb. 16, 2005 (PRIMEZONE) -- Chelsea Therapeutics, Inc., a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of...
-
CHARLOTTE, N.C., Jan. 21, 2005 (PRIMEZONE) -- Chelsea Therapeutics, Inc., ("Chelsea") of CHARLOTTE, NC, and Ivory Capital Corporation ("Ivory") (OTCBB:IVRC), have signed a definitive agreement to...
-
CHARLOTTE, N.C., Jan. 11, 2005 (PRIMEZONE) -- Chelsea Therapeutics, Inc., a privately held development-stage biopharmaceutical company, completed a private placement of Series A Convertible Preferred...